Skip to main content

Table 3 Correlation between lncRNA SNHG16 expression and clinicopathologic parameters for cancers

From: The prognostic value of long noncoding RNA SNHG16 on clinical outcomes in human cancers: a systematic review and meta-analysis

Clinicopathologic parameters No. of studies No. of participants Pooled OR (95% CI) P Model Heterogeneity
Chi2, P-value, I2 (%)
Age (≥ 60/< 60) 5 391 1.06 (0.71, 1.58) 0.79 Fixed 0.38, 0.98, 0
Gender 4 288 1.06 (0.66, 1.70) 0.80 Fixed 2.26, 0.52, 0
Smoking history 3 240 1.03 (0.62, 1.71) 0.90 Fixed 1.94, 0.38, 0
Tumor size (≥ 5 cm/<5 cm) 2 84 6.36 (2.43, 16.60) 0.0002 Fixed 0.02, 0.88, 0
Clinical stage 2 194 2.91 (1.60, 5.28) 0.0005 Fixed 1.29, 0.26, 23
LNM 4 278 4.42 (2.66, 7.35) < 0.00001 Fixed 5.51, 0.14, 46
DM 2 149 3.86 (1.92, 7.77) 0.0002 Fixed 0.84, 0.36, 0
  1. CI confidence interval, DM distant metastasis, LNM lymph node metastasis, OR odds ratio, SNHG16 small nucleolar RNA host gene 16